Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	22.12	8.18	1.37
Research & Development	60.94	28	4.49
Operating Expenses	83.06	36.18	5.85
Operating Income	-83.06	-36.18	-5.85
Interest Expense	-	-	-0.31
Interest & Investment Income	12.14	2.53	-
EBT Excluding Unusual Items	-70.92	-33.65	-6.17
Other Unusual Items	-7.39	-1.12	-
Pretax Income	-78.31	-34.78	-11.62
Income Tax Expense	-	0.01	-
Net Income	-78.31	-34.79	-11.62
Net Income to Common	-78.31	-34.79	-11.62
Shares Outstanding (Basic)	21	2	1
Shares Outstanding (Diluted)	21	2	1
Shares Change (YoY)	1277.25%	93.74%	-
EPS (Basic)	-3.78	-23.10	-14.95
EPS (Diluted)	-3.78	-23.10	-14.95
Free Cash Flow	-67.23	-28.82	-3.85
Free Cash Flow Per Share	-3.24	-19.14	-4.95
EBITDA	-82.22	-36.07	-5.84
D&A For EBITDA	0.84	0.11	0.02
EBIT	-83.06	-36.18	-5.85

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q